Diaceutics PLC (USD) Diaceutics PLC operates as a global diagnostic commercialization entity, providing pharmaceutical companies worldwide with essential data, sophisticated analytics, and implementation support. Central to its offerings is the DXRX platform, a comprehensive suite designed to address various aspects of precision medicine. This platform delivers: DXRX Data Solutions: Granting access to a vast network of laboratory diagnostic testing data. Key components here include DXRX Signal (for specific data insights), Lab Mapping, a Testing Dashboard, and Physician Mapping services. DXRX Marketplace Solutions: A crucial hub that fosters collaborations between laboratories, pharmaceutical firms, and diagnostic companies to advance precision medicine initiatives. DXRX Patient Journey: Enables pharmaceutical clients to conduct in-depth, longitudinal analyses of individual patient biomarker testing pathways. This insight is vital for pinpointing opportunities for earlier intervention and optimized treatment strategies. DXRX Lab Benchmarking: Empowers laboratories to enhance their competitive standing by comparing critical performance metrics – such as disease profiles, testing methodologies, market share, and turnaround times – against industry peers. DXRX Test Reimbursement: Facilitates pharmaceutical companies' engagement with laboratories to secure funding for the launch of novel companion diagnostics, thereby accelerating test adoption and market penetration. DXRX Test Signal: Provides real-time alerts regarding testing events, enabling pharmaceutical clients to quickly identify patients who may benefit from specific therapies. Beyond the DXRX platform, Diaceutics offers a range of supplementary services. These include strategic consulting for precision medicine diagnostics, as well as diagnostic landscape analysis, planning, implementation, and tracking. The company also provides support for test standardization, quality assessment, report optimization, laboratory technical assistance, test access and reimbursement solutions, comprehensive laboratory training, and educational resources. Established in 2005, Diaceutics PLC maintains its headquarters in Belfast, United Kingdom.

Diaceutics PLC (USD) Active

Building Two, Belfast, GB, BT9 6GW

Stock Price USD

Price Change

Last Dividend USD

DIUXF's stock peer is AMEUF (Anteris Technologies Ltd)

DIUXF's stock peer is CMXC (Cell MedX Corp.)

DIUXF's stock peer is CNVCF (BioHarvest Sciences Inc.)

DIUXF's stock peer is COLRF (China Medical & HealthCare Group Limited)

DIUXF's stock peer is EPRXF (Eupraxia Pharmaceuticals Inc.)

DIUXF's stock peer is GREH (Green Rain Energy Holdings Inc.)

DIUXF's stock peer is JMDMF (Japan Medical Dynamic Marketing, Inc.)

DIUXF's stock peer is LFLY (Leafly Holdings, Inc.)

DIUXF's stock peer is LPCUF (Lee's Pharmaceutical Holdings Limited)

DIUXF's stock peer is PSTTF (Prescient Therapeutics Limited)

Healthcare Medical - Diagnostics & Research

Diaceutics PLC operates as a global diagnostic commercialization entity, providing pharmaceutical companies worldwide with essential data, sophisticated analytics, and implementation support. Central to its offerings is the DXRX platform, a comprehensive suite designed to address various aspects of precision medicine. This platform delivers: DXRX Data Solutions: Granting access to a vast network of laboratory diagnostic testing data. Key components here include DXRX Signal (for specific data insights), Lab Mapping, a Testing Dashboard, and Physician Mapping services. DXRX Marketplace Solutions: A crucial hub that fosters collaborations between laboratories, pharmaceutical firms, and diagnostic companies to advance precision medicine initiatives. DXRX Patient Journey: Enables pharmaceutical clients to conduct in-depth, longitudinal analyses of individual patient biomarker testing pathways. This insight is vital for pinpointing opportunities for earlier intervention and optimized treatment strategies. DXRX Lab Benchmarking: Empowers laboratories to enhance their competitive standing by comparing critical performance metrics – such as disease profiles, testing methodologies, market share, and turnaround times – against industry peers. DXRX Test Reimbursement: Facilitates pharmaceutical companies' engagement with laboratories to secure funding for the launch of novel companion diagnostics, thereby accelerating test adoption and market penetration. DXRX Test Signal: Provides real-time alerts regarding testing events, enabling pharmaceutical clients to quickly identify patients who may benefit from specific therapies. Beyond the DXRX platform, Diaceutics offers a range of supplementary services. These include strategic consulting for precision medicine diagnostics, as well as diagnostic landscape analysis, planning, implementation, and tracking. The company also provides support for test standardization, quality assessment, report optimization, laboratory technical assistance, test access and reimbursement solutions, comprehensive laboratory training, and educational resources. Established in 2005, Diaceutics PLC maintains its headquarters in Belfast, United Kingdom.

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions